Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting

LEXINGTON, Mass., May 22, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced that an abstract on its anti-CTLA-4 antibody, AGEN1884 was accepted for poster presentation. The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting will be held in Chicago, IL from June 2-6, 2017.

Agenus Logo

Safety, pharmacokinetic (PK) and pharmacodynamic (PD) readouts will be presented in patients with advanced and refractory malignancies. Early hints of efficacy will also be discussed.

Preclinical data presented at AACR in April indicated an additive pharmacodynamic effect in primate models when Agenus' antibodies targeting CTLA-4 and PD-1 were co-administered. This, along with our clinical data, sets the stage for the Company's plans to combine these two molecules in a Phase 1b study in the second half of this year.

The Company is also developing a next generation antibody targeting CTLA-4 as part of its innovative discovery pipeline.  This novel candidate exploits a distinct mechanism of CTLA-4 antagonism. It exhibits single agent potential and also combines effectively with Agenus' PD-1 antagonist, AGEN2034.

Poster Details

Poster title: Phase 1 open-label, multiple ascending dose trial of AGEN1884, an anti-CTLA-4 monoclonal antibody, in advanced solid malignancies.
Abstract number: #3075
Session title: Developmental Therapeutics - Immunotherapy
Session date and time: Monday June 5, 2017; 8:00 am11:30 am

The poster will become available on the Company's website at following the poster session.

AGEN1884 was developed under a Collaborative Research and Development Agreement between Ludwig Cancer Research, 4-Antibody AG and Recepta Biopharma S.A. AGEN1884 is partnered with Recepta Biopharma S.A. for certain South American rights.

About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing a number of combination approaches that leverage a broad repertoire of antibody therapeutics and proprietary cancer vaccine platforms. The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is based in Lexington, MA. For more information, please visit; information that may be important to investors will be routinely posted on our website.

Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the Company's upcoming poster presentation, plans to disclose safety and efficacy results and clinical trial plans and activities. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.


Agenus Inc. 
Michelle Linn, 781-674-4541


SOURCE Agenus Inc.

print email pdf rss